Physician profile
Larry Ertel
NPI 1063479954
$3,548.25
in general payments reported to CMS, 2019-2025
29 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $198 · 2021: $278 · 2022: $558 · 2023: $473 · 2024: $785 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $367.30 | 2021-2025 | |
| Novo Nordisk INC | $343.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $291.76 | 2019-2025 | |
| Lilly USA, LLC | $236.03 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $219.78 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $201.40 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $197.07 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $153.63 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $126.38 | 2022 | |
| Dynavax Technologies Corporation | $115.37 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $114.50 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $107.71 | 2024-2025 | |
| Abbott Laboratories | $93.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $85.15 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.42 | 2024-2025 | Injectafer |
| Allergan, INC. | $58.55 | 2019-2020 | |
| Neurelis, INC. | $44.61 | 2022 | |
| Shield Therapeutics INC | $44.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.38 | 2021 | |
| Corium, LLC | $33.80 | 2022 | |
| Ironshore Pharmaceuticals INC. | $31.65 | 2019 | |
| Microtransponder, INC. | $19.49 | 2025 | |
| Si-Bone, INC. | $17.53 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.48 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $16.01 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Genentech USA, INC. | $14.68 | 2019 | |
| Esperion Therapeutics, INC. | $12.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Ertel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.